文献速递骨质疏松与代谢性骨病

特立帕肽生物类似药与欧盟及美国获批特立帕肽参比品在健康男性及绝经后女性中的药代动力学、药效学、安全性和免疫原性比较

Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women.
PubMed 文献 · Osteoporos Int · 2022-10-26

本研究在105名健康男性和绝经后女性中开展三周期单剂量交叉试验,随机接受特立帕肽生物类似药INTG-8、欧盟及美国特立帕肽参比品单次皮下20 μg注射。主要药代动力学参数Cmax、AUC0-t和AUC0-∞的几何均值比90%CI均落在80.00%–125.00%等效范围内,证实INTG-8与两种参比品生物等效;药效学、安全性和免疫原性相当,未报告死亡或严重不良事件。

要点

  • INTG-8与欧盟及美国特立帕肽参比品的主要药代动力学参数几何均值比90%CI均在80.00%–125.00%内。
  • 总血清钙水平显示药效学可比。
  • 研究期间未报告死亡或严重不良事件。

核心结论

  • 特立帕肽生物类似药INTG-8与欧盟及美国特立帕肽参比品药代动力学生物等效,药效学、安全性和免疫原性相当。

研究设计与样本

  • 评估者盲、三周期、单剂量交叉研究,105名健康男性和绝经后女性按1:1:1随机接受单次皮下20 μg特立帕肽生物类似药、欧盟特立帕肽或美国特立帕肽注射,连续3天给药。
  • 研究注册于ctri.nic.in(CTRI/2020/10/028627),注册日期2020年10月26日。

主要发现

  • Cmax、AUC0-t和AUC0-∞的几何均值比(试验品:参比品)90%CI均在预设生物等效标准80.00%–125.00%内。
  • 总血清钙水平的药效学可比性通过相似血清钙水平得到证实。
  • 研究治疗总体耐受良好,安全性和免疫原性特征未见有意义差异。
  • 研究期间未报告死亡或严重不良事件。

关键数值与推荐

  • 主要药代动力学参数为Cmax、AUC0-t和AUC0-∞,采用非房室方法分析。
  • 次要药效学终点为总血清钙的最大观察效应(Emax)、从零到最后可测浓度效应曲线下面积(AUE0-t)和达最大观察效应时间(Tmax)。
  • 生物等效性预设标准为几何均值比90%CI在80.00%–125.00%内。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Biosimilar teriparatide (INTG-8) was tested in a healthy population of males and postmenopausal females to assess pharmacokinetic bioequivalence to originator teriparatide comparator products. Primary pharmacokinetic comparison confirmed bioequivalence. Pharmacodynamics, safety, and tolerability were comparable to the originator products. INTG-8 was therefore confirmed to be biosimilar to originator products. INTRODUCTION: The purpose of this present study was to demonstrate pharmacokinetic (PK) equivalence of a biosimilar teriparatide (INTG8) to EU- and US-approved teriparatide reference products in healthy men and postmenopausal women. Secondary objectives included comparison of the pharmacodynamics (PD), safety, and tolerability. METHODS: One hundred and five subjects randomly (1:1:1) received single subcutaneous 20 μg injection of teriparatide biosimilar, EU- and US-teriparatide on 3 consecutive days in this assessor-blind, three-period, single-dose, crossover study. Maximum serum concentration (Cmax), area under the curve (AUC) from time zero to t (AUC0-t), and AUC from time zero extrapolated to infinity (AUC0-∞) were primary PK parameters, analyzed by non-compartmental methods. The secondary PD endpoints were maximum observed effect (Emax), area under the effect curve (AUE) from time zero to the last measurable concentration (AUE0-t), and time to maximum observed effect (Tmax) for total serum calcium levels. Safety, tolerability, and immunogenicity were also evaluated. This study was registered with ctri.nic.in/ (CTRI/2020/10/028627) on 26 October 2020. RESULTS: Baseline demographics were similar across the three-treatment sequence groups. The 90% confidence intervals (CI) for the geometric mean ratios (test:reference) of Cmax, AUC0-t, and AUC0-∞ were within the predefined bioequivalence criterion of 80.00% to 125.00%, which demonstrated PK equivalence of teriparatide biosimilar to EU- and US-teriparatide for all primary endpoints. The PD comparability was demonstrated by similar serum calcium levels. Study treatments were generally well tolerated and showed no meaningful differences in safety or immunogenicity profiles. There were no deaths, or serious AEs were reported during this study. CONCLUSION: The study demonstrated PK bioequivalence of teriparatide biosimilar to the EU- and US-teriparatide reference products with comparable PD, safety, and immunogenicity profiles.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Fenwick S, Vekariya V, Patel R, et al. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women. Osteoporos Int. 2022. PMID: 36287230. doi:10.1007/s00198-022-06573-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。